INS and Hypoglycemia: The mechanism of dapagliflozin is to promote glycemic disposal in an insulin-independent way, thereby decreasing postprandial glycemia and glycemic excursions accompanied by an inferior insulin demand without increasing the risk of hypoglycemia (Li et al., 2022).